Variability in tablet fragment weights when splitting unscored cyclobenzaprine 10 mg tablets

Journal of the American Pharmacists Association

Volumn 44, Issue 5, 2004, Pages 583-586

  Cook, Thomas J ^a   Edwards, Shanya ^a   Gyemah, Charlene ^a   Shah, Manoj ^b   Shah, Indu ^b   Fox, Tiziana ^c  

^a RUTGERS UNIVERSITY   (United States)

^b New Product Development   (United States)

^c McNeil Laboratories Inc   (United States)

Author keywords

Cyclobenzaprine; Dose uniformity; Fragment weight; Tablet splitting; Unscored tablets

Indexed keywords

AMITRIPTYLINE; CYCLOBENZAPRINE; DRUG DERIVATIVE; TRANQUILIZER;

ARTICLE; DRUG FORMULATION; METHODOLOGY; TABLET;

AMITRIPTYLINE; DRUG COMPOUNDING; TABLETS; TRANQUILIZING AGENTS;

EID: 85047687966     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544-3191.44.5.583.Cook     Document Type: Article

References (9)

1. McDevitt JT, Gurst AH, Chen Y. Accuracy of tablet splitting. Pharmacotherapy. 1998;18:193-7.
2. Borenstein DG, Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther. 2003;25:1056-73.
3. TNS Intersearch. Flexeril 10 mg pill splitters-topline results. Data on file. McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, Pa. November 21, 2003.
4. Drug identifier. Accessed at www.efactsweb.com, June 4, 2003.
5. Rosenberg JM, Nathan JP, Plakogiannis F. Weight variability of phar-macist-dispensed split tablets. J Am Pharm Assoc. 2002;42:200-5.
6. Uniformity of Dosage Units. In: USP/NF 2002. The official compendia of standards. Rockville, Md.: The United States Pharmacopeial Convention; 2001:2082-4.
7. Teng J, Song CK, Williams RL, Polli JE. Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc. 2002;42:195-9.
8. National Association of Boards of Pharmacy. Resolution No. 97-4-01, Opposition to mandated tablet splitting. NABP Newsl. 2001;30:7.
9. American Pharmacists Association. Tablet splitting: evaluating appropriateness for patients. J Am Pharm Assoc. 2004;44:324-5.